GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the appointment of six new members to its Board of Directors (the "Board"), effective February 13, 2024. The six new directors are: Dr. ...

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share purchase agreement (the "Purchase Agreement") with an institutional investor (the "Purchaser") for the private ...

BEIJING, Feb. 8, 2024 /PRNewswire/ -- Shareholders of YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced they are convening an extraordinary general meeting of shareholders ("EGM"). The shareholders convening the meeting (the "Convening Shareholders") include Yi Zhang, the founder of YS Biopharma an ...

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies, has released an update note on YS Biopharma Co., Ltd. (NASDAQ:YS). The update note includes information on YS Biopharma's financial results, management commentary, recent developments, outlook, risks, and our revised valuation estimates. The update note is available here. Highlights from the note include: First Half FY 2024 Financial Result Update - In th ...

GAITHERSBURG, Md., Jan. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first half of the fiscal year ended March 31, 2024 (the "first half of fiscal year 2024") ...

Financial Performance - Total revenues for the first half of fiscal year 2024 were RMB273.1 million (US$38.0 million), a decrease of 31.6% compared to RMB399.5 million in the same period of fiscal year 2023[8] - Net loss for the first half of fiscal year 2024 was RMB174.5 million (US$24.3 million), compared to RMB11.1 million in the same period of 2023[13] - Revenues for the six months ended September 30, 2023, were RMB 273,092,454, down from RMB 399,534,723 for the same period in 2022, representing a decrease of about 31.7%[26] - The net loss for the six months ended September 30, 2023, was RMB 174,522,798, compared to a net loss of RMB 11,125,365 for the same period in 2022, reflecting a significant increase in losses[26] - The company reported a basic and diluted loss per share of (1.88) for the six months ended September 30, 2023, compared to (0.18) for the same period in 2022[26] Profitability and Margins - Gross profit was RMB220.9 million (US$30.8 million), with a gross margin of 80.9%, up from 76.5% in the same period of fiscal year 2023[9] - Gross profit for the six months ended September 30, 2023, was RMB 220,905,312, compared to RMB 305,833,944 for the same period in 2022, indicating a decline of approximately 27.8%[26] Expenses - Selling and marketing expenses increased to RMB157.7 million (US$22.0 million) in the first half of fiscal year 2024, up from RMB150.2 million in the same period of fiscal year 2023[10] - Research and development expenses rose to RMB178.9 million (US$24.9 million) in the first half of fiscal year 2024, compared to RMB123.9 million in the same period of fiscal year 2023[12] - Total operating expenses increased from RMB 323,676,199 in the first half of 2022 to RMB 404,163,927 in the first half of 2023, an increase of about 25%[26] Cash and Liquidity - Cash and cash equivalents totaled RMB259.9 million (US$36.2 million) as of September 30, 2023, down from RMB370.4 million as of March 31, 2023[14] - Cash and cash equivalents decreased from RMB 370,108,059 on March 31, 2023, to RMB 259,905,532 on September 30, 2023, a decline of approximately 29.8%[23] - Cash at the end of the period was RMB 259,905,532, up from RMB 227,027,266 at the beginning of the period[32] - Net cash used in operating activities increased to RMB (145,831,735) for the six months ended September 2023, from RMB (107,395,153) in the prior year[32] - Proceeds from bank loans and other borrowings amounted to RMB 201,211,920, while repayments totaled RMB (156,356,071), resulting in net cash provided by financing activities of RMB 44,855,849[32] Assets and Liabilities - Total current assets decreased from RMB 1,035,978,664 on March 31, 2023, to RMB 934,605,218 on September 30, 2023, a decline of approximately 9.8%[23] - Total liabilities rose from RMB 991,300,326 on March 31, 2023, to RMB 1,054,186,774 on September 30, 2023, an increase of approximately 6.3%[23] - Shareholders' equity decreased from RMB 728,453,285 on March 31, 2023, to RMB 557,096,330 on September 30, 2023, a decline of about 23.4%[27] Clinical Development and Patents - The company completed enrollment of 4,500 participants in its Phase III clinical trial for the PIKA rabies vaccine, with interim results expected in the first half of 2024[5] - The United States Patent and Trademark Office issued a patent for PIKA YS-HBV-002, with clinical development expected to commence in 2024[7] Inventory and Depreciation - Write-down of inventories to net realizable value was RMB 10,678,694 for the six months ended September 2023, indicating a significant adjustment[32] - Depreciation of property, plant, and equipment increased to RMB 16,514,915 for the six months ended September 2023, compared to RMB 13,818,386 in the same period of 2022[32] Government Grants and Interest - The company recorded government grants of RMB 14,627,559 for the six months ended September 30, 2023, down from RMB 22,456,691 for the same period in 2022, a decrease of about 34.8%[26] - Interest paid decreased to RMB 10,132,047 for the six months ended September 2023, down from RMB 12,723,051 in the previous year[32] Cash Flows - Cash flows from investing activities showed a net cash outflow of RMB (23,421,694) for the six months ended September 2023, compared to RMB (19,024,351) in the prior year[32] - Non-cash lease expense was RMB 2,452,349 for the six months ended September 2023, slightly up from RMB 2,409,286 in the same period of 2022[32] - Fair value changes of warrant liability resulted in a loss of RMB (6,851,308) during the period[32]

GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company's Board of Directors (the "Board") has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...